Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
InnoCare Pharma Ltd. ( (HK:9969) ) just unveiled an announcement.
InnoCare Pharma Ltd. has announced a board meeting scheduled for November 13, 2025, to review and approve the company’s unaudited third-quarter results for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial health and operational performance, potentially impacting its market position and stakeholder confidence.
The most recent analyst rating on (HK:9969) stock is a Sell with a HK$14.00 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
More about InnoCare Pharma Ltd.
InnoCare Pharma Ltd. is a pharmaceutical company incorporated in the Cayman Islands, focusing on innovative drug development. The company is listed on the Hong Kong Stock Exchange and is involved in the research and production of pharmaceutical products, primarily targeting the healthcare market.
Average Trading Volume: 17,288,640
Technical Sentiment Signal: Buy
Current Market Cap: HK$20.61B
For an in-depth examination of 9969 stock, go to TipRanks’ Overview page.